# A Study to Compare Blood Levels of Different Dosage Formulations of the Study Medicine That Is a CGRP Receptor Antagonist in Healthy Adults

> **NCT07261371** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 64 (actual)

## Conditions studied

- Healthy Volunteer

## Interventions

- **DRUG:** Test formulation (Treatment A)
- **DRUG:** Reference formulation (Treatment B)
- **DRUG:** Test formulation (Treatment C)
- **DRUG:** Test formulation (Treatment D)

## Key facts

- **NCT ID:** NCT07261371
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-11-24
- **Primary completion:** 2026-04-22
- **Final completion:** 2026-04-22
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07261371

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07261371, "A Study to Compare Blood Levels of Different Dosage Formulations of the Study Medicine That Is a CGRP Receptor Antagonist in Healthy Adults". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07261371. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*